BioCentury
ARTICLE | Clinical News

Telik begins Phase II

March 27, 2001 8:00 AM UTC

TELK began an open-label, U.S. Phase II study of its TLK286, a nitrogen mustard alkylating agent prodrug activated by glutathione S-transferase P1-1 (GSTP1-1), in 75 refractory colon cancer patients. ...